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CASE REPORT
 A case of severe psychosis induced by novel recreational drugs
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Abstract
 The use of novel recreational drugs is becoming of publicIntroduction: 
interest, especially after recent international alerts about their cardiovascular
and neurological toxicity. Additionally, little is known about the psychiatric
consequences of the long-term use of these compounds.
We describe a case of severe psychotic episode likelyCase presentation: 
induced by chronic use of a combination of new recreational drugs
(methylenedioxypyrovalerone, mephedrone, butylone and
alpha-pyrrolidinopentiophenone). The patient had no psychiatric history and
showed poor response to conventional antipsychotic treatment (haloperidol).
This case illustrates the potential negative effects of recreationalConclusions: 
drugs that cannot be limited to an acute psychotic episode but might determine
a condition of prolonged paranoid psychosis. Although the use of these
compounds is currently increasing, such molecules might often pass
undetected in patients accessing the emergency room, leading to misdiagnosis
(e.g. schizophrenic episode) and lack of appropriate treatment.
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Case description
We report the case of a 46-y.o. Italian Caucasian man (1.70 m, 70 kg), 
working as a full-time legal consultant.
He was brought to the emergency room of our Psychiatric Depart-
ment in 2013, after having ingested a large quantity of zolpidem, a 
prescription drug indicated for insomnia, with suicidal intent. His 
family history was negative for psychiatric disorders, but he presented 
a positive medical history for liver disease (active chronic hepatitis 
C and Gilbert’s syndrome). He had never suffered from any psychi-
atric symptoms in his childhood, adolescence or early adulthood. 
He had no family history of psychiatric disorders.
The patient’s psychopathological onset occurred three months prior 
to admission when, after continuous use (from one to three times a 
week) of a non-specified recreational drug since July 2012, provided 
to him by a friend who used to buy it online. He developed a per-
secutory delusion, characterized by the conviction of being spied 
upon by some unknown people who placed video cameras around 
his house. In addition, he believed that sexual activity he had with 
his wife was being filmed and then spread on pornographic web-
sites. For this reason, in the following weeks, he made a written 
complaint against unknown persons and presented it to the local 
police office. In addition, one night he called the police force to 
his own home, as he saw suspicious movements outside his win-
dow. On that occasion, the police found out that the patient had a 
gun, which was then confiscated due to security concerns. Thus, the 
police then became part of patient’s delusional plot: the patient 
started thinking his daughter was involved in prostitution and he 
blamed the police for that. These events, along with two formal 
warnings received from his employer (since he did not show up for 
work for many days in a row), and a prolonged condition of global 
insomnia, generated a state of severe discouragement and embar-
rassment in the patient. On account of this he attempted suicide by 
ingesting a large quantity of zolpidem tablets (about 40 tablets of 
10 mg, as related by the patient himself). Zolpidem had been pre-
scribed four months prior to admission by a general practitioner to 
treat the patient’s insomnia.
In the emergency room of our hospital, the patient was initially 
drowsy and slow in his movements, although he was eupneic and 
had stable vital parameters. He underwent a physical examination, 
an electrocardiogram, a chest X-ray and a brain computer tomog-
raphy, which were all normal. Though initially considered appro-
priate, no gastric lavage with activated charcoal was conducted as 
the patient had a spontaneous episode of vomiting. The patient was 
rehydrated with intravenous physiological saline and then admitted 
to our ward.
Since the first day of admission, during the daily interviews with 
the medical staff, the patient showed the same delusional ideas 
described above and showed a very poor insight about his psy-
chopathological condition [Brief Psychiatric Rating Scale (BPRS) 
score=50]. He admitted that the drug he had been taking during 
the previous months might have had a role in the development of 
his thoughts, but this did not change his belief that he was being 
persecuted by the police and his colleagues and managers at work. 
During his hospitalization, which lasted 17 days, his prolonged 
insomnia improved. He developed a mild criticism of his delusion, 
doubting some of the events he had reported, but contemporar-
ily maintained a suspicious behavior towards the nurses and the 
doctors and an overall persecutory ideation. At discharge, he reported 
that he intended to sue the policeman who visited him at home as 
he had no right to suspend his gun license, showing overall poor 
insight and a very solid and structured delusion (BPRS score=31).
As soon as the patient was admitted to our ward, we collected blood 
and urine samples, which were analyzed by the central laboratory 
of our hospital. Haematological and chemistry tests highlighted a 
condition of normocytic anemia (Hb 11.2 mg/dl, Ht 33.4%, mean 
cell volume (MCV) red cells 3.55 × 106/mmc) and a mild hepatic 
distress [alanine transaminase (ALT) 136 U/l]. Routine screening 
for psychotropic drugs gave negative results. A positive emission 
tomography (PET) was performed on the 10th day of admission, 
which showed some unspecific findings consisting of an increased 
glucose metabolism in the basal nuclei but normal levels in the 
cortical regions.
During the hospitalization period, a sample of the drug the patient 
had used for some months, in the form of white powder, was found 
at his home and delivered to the medical staff. This powder sam-
ple, along with further blood and urine samples, were sent to the 
Legal Medicine laboratory in the Forensic Toxicology section of 
our University, after having obtained a regular written consent from 
the patient. A specific analysis on the three samples was conducted 
by means of gas chromatography/mass spectrometry and liquid 
chromatography/high resolution mass spectrometry. The following 
molecules were found by the analysis on the powder: methylenedi-
oxypyrovalerone, mephedrone, butylone and alpha-pyrrolidinopen-
tiophenone (a-PVP) (the proportion of the each was not provided by 
the laboratory) (Table 1). Traces of methylenedioxypyrovalerone 
were found in the urine sample. A test for psychotropic drugs gave 
negative results for the blood sample.
With regards to the psychopharmacological therapy, since the begin-
ning of his hospitalization the patient was treated with haloperidol 
5 mg daily, showing an overall good medication adherence although 
his response was very poor. For this reason, we decided to administer 
an injection of haloperidol decanoate at a dosage of 150 mg (to be 
repeated every 4 weeks, as part of an outpatient regimen). One 
month after his discharge, in a follow-up visit, the patient showed a 
BPRS score of 29, corresponding to a slight improvement in perse-
cutory delusion but no change in insight.
Discussion
In contrast to other reports that show hallucinatory delirium, agi-
tation, anxiety and sleep disturbances following an acute intake 
of more popular substances of abuse (e.g. cannabis, cocaine), we 
describe a clinical picture of a persistent substance-induced psy-
chosis, secondary to a prolonged intake of methylenedioxypyrov-
alerone, mephedrone, butylone and alpha-pyrrolidinopentiophenone 
(a-PVP). The correlation of symptoms with the intake of these 
substances is supposed in the light of a negative psychiatric his-
tory and no concomitant medical treatments. Of note, increased 
glucose metabolism in the basal nuclei at PET was probably due 
to the effects of haloperidol than to the substances, as documented 
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by other reports1. In addition, the moderate hepatic failure of the 
patient could be responsible for the increased availability of the 
drugs and increased toxicity, as hepatic metabolism is involved in 
the excretion of all these substances.
The present report shows the danger of these novel drugs that are 
often bought as apparently safe and legal on the internet. However 
a number of case reports have documented deaths related to the 
ingestion of such substances, especially for mephedrone2 and 
methylenedioxypyrovalerone3,4. A further problem is that these 
substances are not detected by standard blood and urine tests so 
that the diagnosis of intoxication is often delayed. This means that 
patients may not receive the appropriate treatment due to the lack 
of diagnostic tools and may be misdiagnosed as schizophrenic or 
manic bipolar patients. This issue is particularly relevant in the 
emergency department, where a fast and precise diagnosis and 
management of patients is required. In addition, patients leav-
ing the emergency department without being correctly diagnosed 
might continue their abuse and delay specialized follow-up visits 
in an outpatient context, finally developing a condition of chronic 
treatment-resistant psychosis.
These drugs are very popular among young clubbers and mephedrone 
was reported as the sixth most commonly used drug after alcohol, 
tobacco, cannabis, MDMA and cocaine in the dance music scene, 
night clubs and gay bars5–7. Educational campaigns about the risks 
related to these substances are needed in light of the negative effects that 
can be sustained over time8. In addition, clinical pictures similar to 
the one described should not be confused with schizophrenic epi-
sodes despite the atypical presentation and good pre-morbid social 
functioning.
Consent
Consent was obtained from the patient for use of their information 
for publication in this article.
Author contributions
Dr Dragogna and Dr Oldani followed the case and wrote the case 
report. Dr Buoli revised the paper and constructed the table. Professor 
Altamura revised the paper. All authors agreed the final version of 
the manuscript for publication.
Competing interests
Prof. A. Carlo Altamura is a Merck consultant, Astra Zeneca con-
sultant, Sanofi-Aventis speaker’s bureau member, Lilly speaker’s 
bureau member, Pfizer speaker’s bureau member and a Roche 
consultant. Dr Buoli is a Roche consultant. Dr Dragogna and 
Dr Oldani have no competing interests to disclose.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
Table 1. Summary of pharmacological components present in the white powder taken by the patient.
Molecule Mechanism of action Effects Potential risk
Methylenedioxypyrovalerone Norepinephrine-dopamine reuptake inhibitor
Psychic: euphoria, increased 
wakefulness (severe insomnia) 
Physical: tachycardia, hypertension
Hyperthermia3,4 
Mephedrone 
Serotonin-dopamine reuptake 
inhibitor, pre-synaptic 
monoamine release
Psychic: elevated mood, hallucinations, 
delusions, sexual stimulation 
Physical: tachycardia, hypertension, 
breath depression, increased sweating, 
teeth grinding
Stroke, heart failure, 
hyperthermia
Butylone Dopamine reuptake inhibitor, serotonin receptor 2A agonist
Psychic: mild euphoria 
Physical: nystagmus, increased body 
temperature, teeth grinding
Rhabdomyolysis, 
hyperthermia, acute renal 
failure
Alpha-Pyrrolidinopentiophenone 
(a-PVP) 
Norepinephrine-dopamine 
reuptake inhibitor
Psychic: euphoria, anxiety 
Physical: tachycardia, hypertension Hyperthermia
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 George Woody
Treatment Research Institute, University of Pennsylvania, Philadelphia, USA
This is an interesting case report that is clearly written and documents an instance in which a persistent
and treatment resistant psychotic disorder developed after taking an unknown amount of hallucinogenic
and stimulant drugs. This case differs from the typical course of substance induced psychoses in that it
did not resolve with abstinence and pharmacotherapy. I have no suggestions for modifications.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
 No competing interests were disclosed.Competing Interests:
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 John Mendelson
Addiction and Pharmacology Research Laboratory, California Pacific Medical Center Research Institute,
San Francisco, CA, USA
Dragogna and colleagues describe a case of persistent psychosis associated with the ingestion of
mephadrone and related compounds. These cathinone derivatives have similar risks as other
phenethylamine stimulants such as methamphetamine and MDMA and are widely available and easily
abused. It is therefore not surprising that persistent psychosis, as described in this case report, can be
seen with prolonged use.
 
Although the authors show an association of cathinone use with admission for a persistent psychosis the
relationship between cathinone abuse and the development of psychosis is less clear - this patient may
have become psychotic well before using any illicit drugs. However, the case report makes the essential
point that urine drug screens with currently available immunoassay are likely to miss cathinone-like drugs.
Thus, if cathinone use is suspected, a laboratory work up of biospecimes will need to be performed by
groups specializing in medical toxicology. Due to the increasing abuse of drugs in this class clinicians can
expect to see more toxicity. Overall, this report adds to the literature.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
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it is of an acceptable scientific standard.
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